Signal Genetics Inc Share Price Nasdaq
Equities
US8266401046
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 4L 3.08Cr | Sales 2025 * | 3L 2.74Cr | Capitalization | 77Cr 6.42TCr |
---|---|---|---|---|---|
Net income 2024 * | -23Cr -1.91TCr | Net income 2025 * | -27Cr -2.21TCr | EV / Sales 2024 * | 838 x |
Net cash position 2024 * | 46Cr 3.84TCr | Net cash position 2025 * | 63Cr 5.19TCr | EV / Sales 2025 * | 448 x |
P/E ratio 2024 * |
-3.27
x | P/E ratio 2025 * |
-3.09
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Signal Genetics Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01/23/01 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03/18/03 |
Tomas Kiselak
CHM | Chairman | 38 | 28/20/28 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.66% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |